| A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects (NCT05325346) | Veralox Therapeutics | 2022-03-07 |
| Evaluation of the Intra-observer Agreement of the HEP Score in Surgical Intensive Care. (NCT04782843) | Centre Hospitalier Universitaire de Besancon | 2021-03-01 |
| PLATELET Function Assay With Flow Imaging on ImageSTREAM Cytometer (NCT04842760) | Centre Hospitalier Universitaire, Amiens | 2021-03-01 |
| Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban (NCT03809481) | Aspen Global Incorporated | 2019-05-16 |
| Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT) (NCT03594045) | Massachusetts General Hospital | 2018-12-18 |
| Thrombotic Biomarkers to Predict Thrombosis in Heparin-induced Thrombocytopenia (NCT03269019) | Wuhan Asia Heart Hospital | 2017-11-20 |
| Multi-Center Single Arm Trial to Determine The Effectiveness of Warfarin Therapy Duration For Heparin-Induced Thrombocytopenia (HIT) (NCT03147638) | Marshall University | 2017-01-11 |
| Pharmacogenomics of Heparin-Induced Thrombocytopenia (NCT02717039) | University of Arizona | 2016-03-01 |
| Prognosis Related to Induced Thrombopenia With Heparin Under Venoarterial ECMO in Reanimation (NCT03979625) | Central Hospital, Nancy, France | 2016-01-01 |
| Immunogenetics of Heparin-Induced Thrombocytopenia: Aim 2 (NCT02526485) | Vanderbilt University Medical Center | 2015-03-01 |
| Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia (NCT01598168) | McMaster University | 2013-01-01 |
| Heparin-Induced Thrombocytopenia - Retrospective Analysis of Data on Incidence and Outcomes Study (NCT01178333) | Carelon Research | 2010-06-01 |
| Heparin-induced Thrombocytopenia (HIT II) in Liver Transplant Recipients (NCT01654848) | CHIR-Net | 2010-01-01 |
| Validating 4Ts for Heparin Induced Thrombocytopenia (HIT) (NCT00946400) | Medstar Health Research Institute | 2009-08-01 |
| Heparin-Induced Thrombocytopenia: Development and Validation of a Predictive Clinical (NCT00748839) | Centre Hospitalier Universitaire de Saint Etienne | 2009-03-01 |
| Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients (NCT00759083) | The Medicines Company | 2008-09-01 |
| Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT) (NCT00603824) | Methodist Healthcare - Memphis | 2008-01-01 |
| Heparin-Induced Thrombocytopenia Score Card Study (NCT00489437) | McMaster University | 2007-12-01 |
| Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT) (NCT00673439) | University of Louisville | 2007-11-01 |
| Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis (NCT00412464) | Children's Hospital Los Angeles | 2006-09-01 |
| Heparin-Induced Thrombocytopenia Registry (NCT00456326) | Brigham and Women's Hospital | 2005-10-01 |
| Heparin Antibodies in Intensive Care Unit Patients (HAICU) (NCT00283322) | The University of Texas Health Science Center, Houston | 2004-11-01 |
| A Study on the Prevalence of Heparin-Induced Thrombocytopenia in Cardiovascular Patients (NCT00198575) | Ministry of Health, Labour and Welfare, Japan | 2004-11-01 |
| The HIT-TRAP Trial (NCT00196417) | University Medicine Greifswald | 2003-01-01 |
| Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning) (NCT00043940) | The Medicines Company | 1999-04-01 |